Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

January 31, 2008

Conditions
Muscular Dystrophy, Duchenne
Interventions
DRUG

Pentoxifylline

"Participants will be randomized to receive either pentoxifylline or placebo in addition to their stable steroid therapy. Active drug and placebo preparations will be supplied as gel capsules of identical size, appearance and taste. Active drug capsules will contain one 400 mg time-release pentoxifylline tablet and inert filler. Placebo capsules will contain inert filler.~Based on weight at screening, \<30 mg will receive 1 400 capsule/day; 30-49 kg will receive two 400 capsules/day; 50 kg or greater will receive three 400 mg capsules/day."

Trial Locations (11)

1434

Hospital Frances, Buenos Aires

3052

Children's Hospital, Melbourne

15213

Children's Hospital of Pittsburgh, Pittsburgh

20010

Children's National Medical Center, Washington D.C.

27100

IRCCS C Mondino Foundation, Pavia

38104

University of Tennessee, Memphis

55905

Mayo Clinic, Rochester

63110

Washington University, St. Louis, St Louis

91240

Hadassah Hospital, Mt. Scopus, Jerusalem

T2T 5C7

Alberta Children's Hospital, Calgary

T6G 2J3

University of Alberta, Edmonton

All Listed Sponsors
lead

Cooperative International Neuromuscular Research Group

NETWORK

NCT00243789 - Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter